



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

COVID-19 in Lymphangioleiomyomatosis

An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition



To the Editor:

Lymphangioleiomyomatosis is a rare low-grade neoplastic lung disease that occurs sporadically in women or in people with tuberous sclerosis complex. Mechanistic target of rapamycin (mTOR) inhibitors are used for patients with progressive or severe

pulmonary impairment or extrapulmonary manifestations.¹

COVID-19 is associated with worse outcomes in patients with chronic pulmonary diseases.²⁻⁴ However, only a small number of patients with lymphangioleiomyomatosis and COVID-19 have been reported, and the outcomes and impact of mTOR inhibitors on lymphangioleiomyomatosis and COVID-19 infection are unclear.⁵⁻⁷ We conducted an international study to evaluate the consequences of COVID-19 in patients with lymphangioleiomyomatosis and the impact of mTOR inhibitors on outcomes after COVID-19.

Methods

We conducted a retrospective observational study that assessed patients with lymphangioleiomyomatosis receiving care at lymphangioleiomyomatosis clinics in Brazil, the United States, Europe, and Japan who contracted COVID-19 between December 1, 2019, and August 31, 2021. All local institutional ethical committees approved the study.

Demographic and clinical features associated with lymphangioleiomyomatosis, risk factors for poor outcomes resulting from COVID-19, pulmonary function tests closest to COVID-19, use of mTOR inhibitors, symptoms, details if hospitalized, treatments received, and outcomes related to COVID-19 were obtained through

medical records and telephone follow-up. Long COVID-19 was defined as persisting symptoms or new supplemental oxygen use at least 6 weeks after the onset of symptoms.

Normally and nonnormally distributed data are reported as mean \pm SD and as median (interquartile range), respectively. Unpaired *t* tests or the Mann-Whitney *U* test was used to compare continuous variables, whereas the Fisher exact test or χ^2 test was used to compare categorical variables. A univariate and a forward stepwise multivariate logistic regression analysis were performed to identify the predictors of hospitalization or need for supplemental oxygen. *P* values of $< .05$ were considered significant. All analyses were performed using SigmaStat version 3.5 software (Systat Software, Inc.).

Results

Ninety-one women with lymphangioleiomyomatosis (77 with sporadic lymphangioleiomyomatosis, 14 with tuberous sclerosis complex and lymphangioleiomyomatosis) and COVID-19 were identified, with a mean age of 47 ± 12 years and a median time from diagnosis of lymphangioleiomyomatosis of 14 months (interquartile range, 6-78 months). FEV₁ and diffusing capacity of the lungs for carbon monoxide (DLCO) were $73 \pm 23\%$ predicted and $62 \pm 23\%$ predicted, respectively. Forty-seven patients (53%) were using mTOR inhibitors at the time of infection, and 16 patients (17.5%) had at least one comorbidity associated with severe COVID-19 (Table 1).

The most common COVID-19 symptom was asthenia. Corticosteroids were used in 26.4% of patients,

antibiotics were used in 17.6% of patients, anticoagulants were used in 11% of patients, azithromycin was used in 7.7% of patients, and remdesivir was used in 5.5% of patients. Fifty-three patients (58.2%) received no specific drug treatment. Twenty-eight patients (31%) required hospital admission with a mean stay of 11 ± 8 days, two patients (2.2%) required noninvasive ventilation, and two patients (2.2%) required mechanical ventilation. One patient, 59 years of age with severe lymphangioleiomyomatosis, died (oxygen dependent with FEV₁ of 32% predicted). Twenty patients (22%) received a diagnosis of long COVID-19, mainly fatigue (Table 1). None of the patients were vaccinated against SARS-CoV-2 when they contracted COVID-19. Patients who were hospitalized or needed supplemental oxygen showed worse pulmonary function (FEV₁ % predicted: $63 \pm 22\%$ vs $79 \pm 21\%$; *P* = .002; DLCO % predicted: 49

TABLE 1] Demographic, Clinical, and Functional Characteristics and Outcomes of Patients With Lymphangioleiomyomatosis Who Received a Diagnosis of COVID-19 (N = 91)

Variable	Data
Demographic and clinical data	
Country	
United States	23 (25.3)
Brazil ^a	20 (22)
Poland	20 (22)
United Kingdom	16 (17.5)
France	6 (6.6)
Italy	3 (3.3)
The Netherlands	2 (2.2)
Japan	1 (1.1)
Age, y	47 ± 12
Race or ethnicity	
White	76 (83.5)
Black	4 (4.4)
Hispanic	8 (8.8)
Asian	3 (3.3)
Subtype of lymphangioleiomyomatosis	
Sporadic	77 (84.6)
Associated with TSC	14 (15.4)
Time from diagnosis of lymphangioleiomyomatosis, mo	14 (6-78)
BMI ≥ 30 kg/m ²	21 (23.1)
Comorbidities	
Diabetes	6 (6.6)
Cancer	3 (3.3)
Chronic kidney disease	6 (6.6)
Heart failure, coronary artery disease, or cardiomyopathy	0
Sickle cell disease	1 (1.1)
Previous organ transplantation	0
Current pregnancy	0
Smoking (former or current)	14 (15.4)
Use of mTOR inhibitors before COVID-19 ^b	47 (52.8)
Sirolimus	44 (49.4)
Everolimus	3 (3.4)
Dose of sirolimus, mg	2 (1-2)
Dose of everolimus, mg	5 (5-8.75)
Duration of mTOR inhibitor use, mo	44 (12-70)

(Continued)

TABLE 1] (Continued)

Variable	Data
Pulmonary function tests	
FEV ₁ , L	2.13 ± 0.77
FEV ₁ , % predicted	73 ± 23
FVC, L	3.05 ± 0.82
FVC, % predicted	88 ± 21
DL _{CO} , mL/min/mm Hg	7.84 (5.71-17.00)
DL _{CO} , % predicted	62 ± 23
COVID-19 diagnosis	
RT-PCR swab	87 (95.6)
COVID-19 seroconversion and clinical manifestations	4 (4.4)
Symptoms during COVID-19	
Asthenia	80 (87.9)
Fever	64 (70.3)
Cough	64 (70.3)
Anorexia	48 (52.7)
Dyspnea	43 (47.3)
Headache	40 (44)
Anosmia	38 (41.8)
Dysgeusia	33 (36.3)
Diarrhea	20 (22)
Other ^c	10 (11)
Hospital admission	
Hospital admission	28 (30.8)
Duration of hospital stay, d	11 ± 8
Supplemental oxygen use	27 (29.7)
Duration of supplemental oxygen use, d	7 (5-14)
Duration of mechanical ventilation, d	14 (6-22)
Suspension of mTOR inhibitors	21 (44.7)
Outcomes	
Death	1 (1.1)
New or increased supplemental oxygen	10 (11)
Pulmonary embolism	1 (1.1)
Pneumothorax	1 (1.1)
Long COVID-19 ^d	20 (22)

Data are presented as No. (%), mean ± SD, or median (interquartile range). DL_{CO} = diffusing capacity of the lungs for carbon monoxide; mTOR = mechanistic target of rapamycin; RT-PCR = reverse-transcription polymerase chain reaction; TSC = tuberous sclerosis complex.

^aPartial information about six patients from Brazil was described in a previous report.⁵

^bTwo patients were enrolled in a double-blind placebo-controlled trial of sirolimus vs placebo, and therefore were not included in this analysis.

^cOther symptoms include nausea, chest pain, night sweats, myalgia, sore throat, and dysphonia.

^dThe most common manifestation of long COVID-19 was fatigue.

± 21% vs 69 ± 20%; $P < .001$) than those treated at home without supplemental oxygen. No difference was found in the need for hospitalization or supplemental oxygen, nor in the duration of hospitalization, segregating the cohort on the basis of underlying BMI ($\geq 25 \text{ kg/m}^2$ vs $< 25 \text{ kg/m}^2$ or $\geq 30 \text{ kg/m}^2$ vs $< 30 \text{ kg/m}^2$; data not shown).

Patients using mTOR inhibitors demonstrated lower lung function, a higher frequency of dyspnea, and

greater need for hospital admission and supplemental oxygen during the course of COVID-19 compared with untreated patients. Use of mTOR inhibitors had no effect on length of hospital stay or need for oxygen or ventilatory support (Table 2). In the univariate analysis, FEV₁ (% predicted; OR, 0.97; 95% CI, 0.95-0.99; $P = .005$), DLCO (% predicted; OR, 0.95; 95% CI, 0.93-0.98; $P = .001$), and use of mTOR inhibitors (OR, 3.23; 95% CI, 1.27-8.21; $P = .01$)

TABLE 2] Comparison of Patients Separated by mTOR Inhibitor Treatment (n = 89)^a

Variable	Patients Using mTOR Inhibitors (n = 47)	Patients Not Using mTOR Inhibitors (n = 42)	P Value
Clinical and functional features			
Age, y	47 ± 10	47 ± 13	.96
BMI ≥ 30 kg/m ²	9 (19.1)	11 (26.2)	.59
At least one comorbidity ^b	9 (19.1)	7 (16.7)	.98
Smoking (former or current)	7 (14.9)	7 (16.7)	.98
Time from diagnosis of lymphangioleiomyomatosis, mo	17 (6.25-96)	13.5 (6-42)	.52
FEV ₁ , % predicted	66 ± 24	80 ± 18	.004
DLCO, % predicted	55 ± 22	69 ± 20	.005
Symptoms during COVID-19			
Asthenia	42 (89.4)	36 (85.7)	.84
Fever	37 (78.7)	25 (59.5)	.08
Cough	34 (72.3)	29 (69)	.91
Anorexia	26 (55.3)	20 (47.6)	.61
Dyspnea	28 (59.6)	15 (35.7)	.04
Headache	22 (46.8)	17 (40.5)	.70
Anosmia	20 (42.6)	18 (42.9)	.85
Dysgeusia	16 (34)	17 (40.5)	.68
Diarrhea	10 (21.3)	9 (21.4)	.81
Hospital admission			
Hospital admission	20 (42.6)	8 (19)	.03
Supplemental oxygen use	18 (38.3)	9 (21.4)	.13
Hospital admission or supplemental oxygen use	22 (46.8)	9 (21.4)	.02
Duration of supplemental oxygen use, d	7 (7-14)	7 (3-15)	.57
Noninvasive ventilation	2 (4.3)	0	.50
Mechanical ventilation	2 (4.3)	0	.50
Duration of hospital stay, d	8 (5-12)	12 (5-20)	.38
Outcomes			
Death	1 (2.1)	0	1.00
New or increased supplemental oxygen after COVID-19	7 (14.9)	3 (7.1)	.32
Pulmonary embolism	0	1 (2.4)	.47
Pneumothorax	1 (2.1)	0	1.00
Long COVID-19	12 (25.5)	8 (19)	.63

Data are presented as No. (%), mean ± SD, or median (interquartile range). Boldface indicates statistical significance. DLCO = diffusing capacity of the lungs for carbon monoxide; mTOR = mechanistic target of rapamycin.

^aTwo patients were enrolled in a double-blind placebo-controlled trial of sirolimus vs placebo, and therefore were not included in this analysis.

^bDiabetes, cancer, chronic kidney disease, heart failure, coronary artery disease or cardiomyopathy, and sickle cell disease.

were predictors of hospitalization or need for supplemental oxygen. However, in the multivariate analysis, only DLCO (% predicted; OR, 0.96; 95% CI, 0.93-0.99; $P = .02$) was associated with the need for hospitalization or supplemental oxygen.

Discussion

To our knowledge, this is the largest study of COVID-19 in patients with lymphangioleiomyomatosis. The major findings are: (1) approximately one-third of the patients with lymphangioleiomyomatosis required hospitalization after COVID-19, with one death among 91 patients; (2) reduced DLCO was associated with the need for hospitalization and need for supplemental oxygen; and (3) the overall outcomes were similar in patients receiving mTOR inhibitors vs those not receiving mTOR inhibitors.

Multiple cohort studies have demonstrated an increased risk of severe COVID-19 and death in patients with pre-existing chronic lung diseases.²⁻⁴ When comparing women with lymphangioleiomyomatosis with a general population of comparable age (30-59 years), need for hospitalization was greater (31% vs 9.5%), but no increase in mortality was found (1.1% vs 1.3%),⁸ suggesting that women with lymphangioleiomyomatosis may not be at an increased risk of poor outcomes after COVID-19. The younger age of women with lymphangioleiomyomatosis in our study in part may explain the better outcomes compared with patients with other chronic pulmonary diseases. The prevalence of persistent symptoms at 6 weeks after infection (long COVID-19) of 22% in this lymphangioleiomyomatosis cohort is also similar to that in the general population.⁹

The impact of mTOR inhibitors on COVID-19 outcomes is not well understood. Although it is generally believed that patients with underlying immunosuppression are at increased risk of COVID-19-related complications,² it has been speculated that mTOR inhibitors may have a beneficial impact in patients with COVID-19 owing to their in vitro inhibitory effects on viral replication and their potential to mitigate cytokine storm.¹⁰ In a small series from Brazil of six patients with lymphangioleiomyomatosis who received a diagnosis of COVID-19, half were using sirolimus, and all completely recovered from the infection.⁵ In the present study, the use of mTOR inhibitors was not associated with worse outcomes, despite these patients having poorer lung function than untreated patients, which should provide reassurance

to patients with lymphangioleiomyomatosis and clinicians.

Our study has several limitations. The number of patients with lymphangioleiomyomatosis who received a diagnosis of COVID-19 may have been underestimated because of our criteria limiting inclusion to confirmed cases, which excluded asymptomatic patients and patients who were not tested. Most of the patients in our study contracted COVID-19 before the widespread availability of COVID-19 vaccines or the worldwide emergence of the delta variant, and the impact of these variables on outcomes after COVID-19 in patients with lymphangioleiomyomatosis remains unknown. Asthenia is experienced frequently by women with lymphangioleiomyomatosis and might have led to the overestimation of prevalence of long COVID-19 in our study. Other limitations include the lack of a control group or propensity score matching and the nonstandardized and evolving treatment paradigms for COVID-19 in different countries. Additionally, some of the results obtained may be explained by a type II error. However, these limitations are mitigated by the inclusion of data from multiple international centers and the relatively large sample size for a rare disease.

In conclusion, this multicenter study demonstrated that the risks of death and long COVID-19 after COVID-19 infection in women with lymphangioleiomyomatosis are similar to those of the general population and that mTOR inhibitor use is not associated with worse outcomes.

Bruno Guedes Baldi, MD, PhD
São Paulo, Brazil

Elzbieta Radzikowska, MD, PhD
Warsaw, Poland

Vincent Cottin, MD
Lyon, France

Daniel F. Dilling, MD
Maywood, IL

Ali Ataya, MD
Gainesville, FL

Carlos Roberto Ribeiro Carvalho, MD, PhD
São Paulo, Brazil

Sergio Harari, MD
Milan, Italy

Matthew Koslow, MD
Denver, CO

Jan C. Grutters, MD, PhD
Utrecht, The Netherlands

Yoshikazu Inoue, MD, PhD
Osaka, Japan
Nishant Gupta, MD
Cincinnati, OH
Simon R. Johnson, DM
Nottingham, England

AFFILIATIONS: From the Divisão de Pneumologia (B. G. Baldi and C. R. R. Carvalho), Instituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo; the National Tuberculosis and Lung Diseases Research Institute (E. Radzikowska); the National Reference Center for Rare Pulmonary Diseases (V. Cottin), Louis Pradel Hospital, Hospices Civils de Lyon, University of Lyon, INRAE; the Division of Pulmonary and Critical Care (D. F. Dilling), Loyola University Chicago, Stritch School of Medicine; the Division of Pulmonary, Critical Care and Sleep Medicine (A. Ataya), University of Florida; the Division of Pulmonary, Critical Care and Sleep Medicine (N. Gupta), University of Cincinnati; the ILD Program (M. Koslow), Department of Medicine, National Jewish Health; the Department of Clinical Sciences and Community Health (S. Harari), University of Milan, the Department of Medicine (S. Harari), Ospedale San Giuseppe MultiMedica IRCCS; the ILD Center of Excellence (J. C. Grutters), St. Antonius Hospital Nieuwegein, University Medical Center Utrecht; the Clinical Research Center (Y. Inoue), National Hospital Organization Kinki-Chuo Chest Medical Center; Translational Medical Sciences (S. R. Johnson), NIHR Biomedical Research Centre and Bioscience Institute, University of Nottingham, and the National Centre for Lymphangioleiomyomatosis (S. R. Johnson), Nottingham University Hospitals NHS Trust.

Drs Gupta and Johnson contributed equally to this manuscript.

FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to *CHEST* the following: D. F. D. is a member of the board of directors of the LAM Foundation. Y. I. reports advising of and lecture fees from Boehringer Ingelheim, Taiho, Roche, Shionogi, Galapagos, and Savara. None declared (B. G. B., E. R., V. C., A. A., C. R. R. C., S. H., M. K., J. C. G., N. G., S. R. J.).

FUNDING/SUPPORT: D. F. D. is supported by the National Institutes of Health [Grant U01HL131755]. Y. I. is supported by the Japanese Ministry of Health Labour, and Welfare. N. G. is supported by the National Institutes of Health [Grants U01HL131755 and R34HL138235] and the LAM Foundation. S. R. J. is supported by the Medical Research Council, National Institute for Health Research, British Lung Foundation, LAM Action, and the LAM Foundation.

CORRESPONDENCE TO: Bruno Guedes Baldi, MD, PhD; email: bruno.baldi@hc.fm.usp.br

Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

DOI: <https://doi.org/10.1016/j.chest.2021.12.640>

Acknowledgments

Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript.

Other contributions: The authors thank Roberto Cassandro, MD, Gregory Downey, MD, Dominique Israel-Biet, MD, PhD, Masaki Hirose, MD, Francis McCormack, MD, Hilario Nunes, MD, PhD, and Yurdagül Uzunhan, MD, PhD for contributing participants to this study.

References

1. McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. *Am J Respir Crit Care Med*. 2016;194(6):748-761.
2. Drake TM, Docherty AB, Harrison EM, et al. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. *Am J Respir Crit Care Med*. 2020;202(12):1656-1665.
3. Galloway L, Uzunhan Y, Borie R, et al. Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease. *Am J Respir Crit Care Med*. 2021;203(2):245-249.
4. Aveyard P, Gao M, Lindson N, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study [published online ahead of print April 1, 2021]. *Lancet Respir Med*. [https://doi.org/10.1016/S2213-2600\(21\)00095-3](https://doi.org/10.1016/S2213-2600(21)00095-3)
5. Baldi BG, Amaral AF, de Figueiredo Braga Colares P, Kairalla RA, Oliveira MR, Carvalho CRR. COVID-19 and lymphangioleiomyomatosis: experience at a reference center and the potential impact of the use of mTOR inhibitors. *Am J Med Genet A*. 2020;182(12):3068-3070.
6. Peron A, La Briola F, Bruschi F, et al. Tuberous sclerosis complex (TSC), lymphangioleiomyomatosis, and COVID-19: the experience of a TSC clinic in Italy. *Am J Med Genet A*. 2020;182(11):2479-2485.
7. Zheng Y, Li R, Liu S. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: a novel intervention strategy beyond vaccines and specific antiviral medicines. *J Med Virol*. 2020;92:1495-1500.
8. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(24):759-765.
9. Office for National Statistics. Prevalence of long COVID symptoms and COVID-19 complications. 16 December 2020. Office for National Statistics website. Accessed October 1, 2021, <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complications>
10. Patocka J, Kuca K, Oleksak P, et al. Rapamycin: drug repurposing in SARS-CoV-2 infection. *Pharmaceuticals (Basel)*. 2021;14(3):217.